Develops TCR-guided NK cell therapies for solid tumours
| Date | Round | Amount |
|---|---|---|
| Aug 2022 | Funding round Oslo biopharma Zelluna Immunotherapy received an undisclosed investment from Takeda Ventures to advance its cancer cell therapy platform. | — |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.